Bio Essence Corp (BIOE) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
2955 MAIN STREET IRVINE, CA 92614 |
| State of Incorp. | CA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 1 | 0 | 6 | 0 | |||
| Cash and cash equivalent | 1 | 0 | 6 | 0 | |||
| Receivables | 5 | 955 | 6 | 17 | |||
| Inventory, net of allowances, customer advances and progress billings | 143 | 181 | 213 | ||||
| Inventory | 143 | 181 | 213 | ||||
| Prepaid expense | 6 | 9 | 32 | ||||
| Advances on inventory purchases | 70 | 2 | |||||
| Deposits current assets | 2 | ||||||
| Other undisclosed current assets | 202 | ||||||
| Total current assets: | 281 | 1,104 | 204 | 262 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 1,428 | 1,055 | 1,213 | ||||
| Property, plant and equipment | 35 | 246 | 181 | ||||
| Intangible assets, net (including goodwill) | 1 | 1 | 1 | ||||
| Intangible assets, net (excluding goodwill) | 1 | 1 | 1 | ||||
| Deposits noncurrent assets | 42 | 42 | |||||
| Other noncurrent assets | 0 | ||||||
| Other undisclosed noncurrent assets | 94 | ||||||
| Total noncurrent assets: | 0 | 1,558 | 1,344 | 1,437 | |||
| TOTAL ASSETS: | 281 | 2,662 | 1,548 | 1,699 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 20 | 173 | 75 | 88 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 13 | ||
| Taxes payable | ✕ | ✕ | ✕ | ✕ | 12 | ||
| Accounts payable | 18 | 170 | 50 | 63 | |||
| Accrued liabilities | 2 | 3 | 25 | ||||
| Debt | 18 | 78 | 31 | ||||
| Government assistance, liability | 1 | ✕ | ✕ | ✕ | |||
| Other undisclosed current liabilities | 2,781 | 2,992 | 3,405 | 2,637 | |||
| Total current liabilities: | 2,803 | 3,183 | 3,558 | 2,756 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 1 | 65 | 1,161 | ||||
| Long-term debt, excluding current maturities | 26 | 38 | |||||
| Finance lease, liability | 1 | 40 | 1,123 | ||||
| Liabilities, other than long-term debt | 447 | 938 | 953 | ||||
| Other liabilities | 447 | ||||||
| Operating lease, liability | 938 | 953 | |||||
| Government assistance, liability | ✕ | ✕ | ✕ | ||||
| Other undisclosed noncurrent liabilities | 200 | 210 | 211 | ||||
| Total noncurrent liabilities: | 447 | 1,139 | 1,228 | 1,372 | |||
| Total liabilities: | 3,250 | 4,322 | 4,786 | 4,128 | |||
| Equity | |||||||
| Equity, attributable to parent | (2,969) | (1,660) | (3,238) | (2,429) | |||
| Common stock | 4 | 4 | 3 | 3 | |||
| Additional paid in capital | 7,476 | 7,476 | 4,927 | 4,927 | |||
| Accumulated deficit | (10,449) | (9,140) | (8,169) | (7,359) | |||
| Total equity: | (2,969) | (1,660) | (3,238) | (2,429) | |||
| TOTAL LIABILITIES AND EQUITY: | 281 | 2,662 | 1,548 | 1,699 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|---|
| Revenues | 324 | 552 | 986 | 888 | ||
| Other income | 6 | 266 | ||||
| Cost of revenue | (107) | (274) | (601) | (590) | ||
| Cost of product and service sold | (274) | (54) | (92) | |||
| Gross profit: | 217 | 277 | 385 | 298 | ||
| Operating expenses | (677) | (1,066) | (1,168) | (1,156) | ||
| Other operating expense, net (Other Expenses) | (1) | (5) | ||||
| Other undisclosed operating income | 1 | 5 | ||||
| Operating loss: | (459) | (789) | (783) | (858) | ||
| Nonoperating expense | (1,105) | (11) | (5) | (10) | ||
| Other nonoperating income (expense) | (52) | (11) | ||||
| Interest and debt expense | (2) | (17) | (2) | (47) | ||
| Loss from continuing operations before equity method investments, income taxes: | (1,567) | (817) | (790) | (914) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 2 | 17 | (17) | 270 | ||
| Loss from continuing operations before income taxes: | (1,565) | (800) | (806) | (644) | ||
| Income tax expense | (1) | (2) | (3) | (3) | ||
| Loss from continuing operations: | (1,566) | (803) | (810) | (648) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (648) | |
| Loss from discontinued operations | (237) | |||||
| Net loss: | (1,566) | (1,039) | (810) | (648) | ||
| Other undisclosed net income attributable to parent | 257 | 67 | ||||
| Net loss available to common stockholders, diluted: | (1,309) | (972) | (810) | (648) | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|---|
| Net loss: | (1,566) | (1,039) | (810) | (648) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,566) | (1,039) | (810) | (648) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.